Therapeutic Effect of Back-shu Point Catgut Embedding in Spleen-stomach Deficiency Type I and II Myasthenia Gravis
- Conditions
- Myasthenia Gravis
- Registration Number
- ITMCTR1900002613
- Lead Sponsor
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Diagnosed with Myasthenia Gravis based on the diagnostic criteria of Practical internal science (Peoples Medical Publishing House The 15th edition)and patients with MG belonging to the the modifed Osseman III type;
2. Diagnosed with Chinese medical diagnosis of flaccidity fitting to the differentiation standard of spleen-stomach deficiency type;
3. Aged 18 to 75-year-old;
4. Sign informed consent.
1. Osseman III, IV, V;
2. Familial MG, congenital myasthenic syndrome and drug (D-penicillamine, interferon induced by MG, etc.);
3. Patients who were nursing or pregnant;
4. Patients who had comorbid diseases such as cerebrovascular diseases, renal insufficiency, hematopoietic system diseases, and psychiatric diseases;
5. Patients who has contraindications for embedding;
6. Allergies (allergic to more than 2 kinds of food or medicine);
7. The last 3 months participated in other clinical trials of drugs.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MG-ADL grade;TCM Syndrome Efficacy Criteria scores;MGC scores;MG-QOL15;
- Secondary Outcome Measures
Name Time Method